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Computed tomographic angiography (CTA) and magnetic resonance angiography (MRA) are increasingly used 
to assess arterial patency in patients with ischemic stroke.1,2 
Angiography may also improve selection of patients with 
ischemic stroke for treatment with intravenous thrombolyt-
ics. However, it is unclear if arterial obstruction, or collateral 
Background and Purpose—Computed tomographic angiography and magnetic resonance angiography are used increasingly 
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functional outcome (Oxford Handicap Scale) and tested for interactions with alteplase, using ordinal regression in 
adjusted analyses. We also meta-analyzed all available angiography data from other randomized controlled trials of 
intravenous thrombolytics.
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resonance angiography=29). On multivariable analysis, more extensive angiographic obstruction and poor collaterals 
independently predicted poor outcome (P<0.01). We identified no significant interaction between angiography findings 
and alteplase effect on Oxford Handicap Scale (P≥0.075) in IST-3. In meta-analysis (5 trials of alteplase or desmoteplase, 
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supply, influences the response to intravenous thrombolyt-
ics. A retrospective stroke registry observed a trend for more 
favorable clinical outcome after intravenous alteplase in 
patients with intracranial arterial occlusion versus those with 
no/minimal obstruction in whom it was unclear if intravenous 
alteplase was beneficial or not.3
Few randomized controlled trials (RCTs) of intrave-
nous thrombolytics included CTA or MRA to determine 
whether angiographic obstruction–occlusion or collateral 
supply modifies the treatment response. A pooled analysis 
of DIAS (Desmoteplase in Acute Ischemic Stroke), DIAS-
2, and DEDAS (Dose Escalation of Desmoteplase for Acute 
Ischemic Stroke) demonstrated that patients with complete 
arterial occlusion or severe obstruction had better outcomes 
after desmoteplase than placebo, but in patients with minimal 
obstruction or normal arteries, there was no significant dif-
ference between desmoteplase versus placebo.4 In EPITHET 
(Echoplanar Imaging Thrombolytic Evaluation Trial), patients 
with middle cerebral artery (MCA) rather than internal carotid 
artery (ICA) obstruction demonstrated better outcome after 
intravenous alteplase, but they did not test for an alteplase–
arterial patency interaction.5
The IST-3 (Third International Stroke Trial) was a large 
(n=3035) RCT that tested whether intravenous alteplase given 
within 6 hours of ischemic stroke improved functional out-
come at 6 months compared with control.6 In IST-3, some 
centers routinely performed CTA or MRA prerandomization. 
As prespecified,7 we investigated whether arterial obstruction 
or collateral status on prerandomization CTA and MRA influ-
enced outcome after alteplase versus control. In addition, we 
meta-analyzed all RCTs of intravenous thrombolytics in isch-
emic stroke with baseline angiography data.
Methods
Third International Stroke Trial
IST-3 was an international, multicenter, PROBE trial (prospective, 
randomized, open-label, blinded end point) of intravenous alteplase 
in acute ischemic stroke. Ethical approval was granted by the 
Multicentre Research Ethics Committees, Scotland (MREC/99/0/78) 
and by local ethics committees. Enrollment, randomization, data 
collection and analysis, and adherence to CONSORT (Consolidated 
Standards of Reporting Trials) recommendations have been pub-
lished.6,8,9 Briefly, adults with acute stroke of any severity, in whom 
CT or MR imaging had excluded intracranial hemorrhage and struc-
tural stroke mimics, who did not meet the prevailing license crite-
ria for alteplase but had no clear contraindication to treatment, were 
eligible for the trial if treatment could be started within 6 hours of 
known stroke onset. Informed consent was obtained for all patients. 
Baseline stroke severity before randomization was assessed with the 
National Institutes of Health Stroke Scale (NIHSS). After entry of 
baseline data, patients were randomly allocated to immediate intra-
venous alteplase (0.9 mg/Kg) or control. Functional outcome was 
assessed at 6 months with the Oxford Handicap Scale (OHS), which 
is similar to the modified Rankin Scale.
Angiographic Imaging in IST-3
IST-3 centers that routinely performed CTA or MRA in stroke sub-
mitted these images for assessment. Here, we include only IST-3 
patients with angiography performed prerandomization. Images 
were anonymized and uploaded to a web-based rating platform, the 
Systematic Image Review System V2. Systematic Image Review 
System V2 provides secure anonymized image viewing via a browser 
(http://www.neuroimage.co.uk) and simultaneously records the scan 
interpretation using a validated proforma10,11 (http://www.sbirc.ed.ac.
uk/research/imageanalysis.html).
All angiographic imaging in IST-3 was assessed centrally by 
a panel of 10 experts in stroke imaging (7 neuroradiologists and 3 
neurologists/stroke physicians). Readers were masked to all clinical, 
treatment, and functional outcome data and to imaging from different 
time points (concurrent plain scans were viewed with angiography). 
IST-3 angiography was analyzed independently from the plain CT 
and MR imaging scans of the main IST-3 trial.
Scan readers recorded the presence, location, and severity of all 
arterial obstructions, largest affected artery first plus ≤2 additional 
segments (Table I in the online-only Data Supplement). Locations 
were ICA, MCA, anterior cerebral artery, posterior cerebral artery, 
vertebral artery, or basilar artery. We grouped arterial segments as 
proximal (ICA, main stem MCA, vertebral artery, and basilar artery) 
or distal (Sylvian branch of MCA, anterior cerebral artery, and pos-
terior cerebral artery).
Readers coded the focus of arterial obstruction using a modified 
Thrombolysis in Cerebral Infarction (TICI) and the IST-3 angiogra-
phy scores.7,12 Both are scalar and range from occlusion (0), through 
decreasing grades of obstruction, to normal (3 for TICI and 4 for IST-
3). For this analysis, we categorized the IST-3 score 0 to 2b and the 
TICI score 0 to 2a as obstruction and IST-3 score 3 to 4 and the TICI 
score 2b to 3 as patent.
Readers also coded the clot burden score in patients with anterior 
circulation obstruction (subtracts the sum of the number of arterial 
segments affected from 10,13 where score 0=all segments affected and 
10=no segments affected) and the collateral vessel supply in patients 
with ICA or MCA obstruction (categorized as good where the entire 
MCA distal to obstruction reconstituted with contrast, moderate 
where there was some MCA branch reconstitution, or poor if only 
distal superficial branches reconstituted).14
We tested previously interobserver reliability for the IST-3 panel’s 
CTA assessments (but because of the small number of cases, not 
MRA) on 15 representative scans,15 finding substantial agreement 
for arterial obstruction on TICI, IST-3 angiography, and clot burden 
scores (Krippendorff α=0.60, 0.66, and 0.63, respectively) and mod-
erate agreement for collateral score (0.56).
Statistical Analysis: IST-3 Angiography Data
For univariate analysis of normally distributed data, we compared 
ratios and means with t tests; for nonparametric data, we used Mann–
Whitney U tests to compare medians and Spearman ρ to assess for 
correlation. We used multifactor ANOVA to look for interactions 
between combinations of angiographic findings and OHS. To test for 
associations between angiography findings, alteplase versus control 
and outcome, we used multivariable ordinal regression to calculate 
common odds ratios (ORs) with OHS at 6 months as the dependent 
variable. We first tested the impact of different angiography charac-
teristics on outcome individually, controlled for patient age, NIHSS, 
time from stroke onset to scan, and alteplase treatment allocation 
(here, OR <1 indicates worse outcome with alteplase). We then com-
pared alteplase treatment effect on outcome (here, OR <1 favors 
control) for dichotomies (more normal versus less normal) of each 
angiography characteristic individually, controlled for patient age, 
NIHSS, and time from stroke onset to scan and tested for treatment 
interactions by comparing ORs between dichotomies. For this lat-
ter analysis only, we dichotomized clot burden and collateral scores 
as better (8–9 and good) versus worse (0–7 and moderate–poor, 
respectively).
Meta-Analysis
We identified all RCTs comparing intravenous thrombolytics with 
control among patients with baseline angiography after ischemic 
stroke from the Cochrane Collaboration systematic review on 
“Thrombolysis for Acute Ischaemic Stroke”16 and contacted investi-
gators for additional data where necessary. We used the random effects 
method to perform 2 separate meta-analyses to obtain summary ORs 
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for the effect of intravenous thrombolytics (any formulation or dose) 
on outcome (OHS or mRS at 3–6 months) in patients with (1) arte-
rial obstruction (IST-3 angiography score 0 to 2b or Thrombolysis 
in Myocardial Infarction 0–1 or 0–2) versus patent vessels (IST-3 
angiography score 3–4 or Thrombolysis in Myocardial Infarction 
2–3 or 3) and (2) ICA versus MCA obstruction, including tests for 
interactions between intravenous thrombolytics and arterial status on 
functional outcome. We tested for between-study heterogeneity using 
I2 statistics. We followed Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines for meta-analysis 
reporting (Appendix II in the online-only Data Supplement).
We used Comprehensive Meta-Analysis software (Biostat, 
Englewood, NJ) to compute summary ORs and test for interactions. 
We performed all other analyses using IBM SPSS Statistics soft-
ware, version 20.0 (IBM Corporation, Armonk, NY). We considered 
P<0.05 significant.
Results
Third International Stroke Trial
From 3035 IST-3 patients, 300 (9.9%) had prerandomization 
angiography, 271 with CTA, 29 with MRA. Compared with 
the full IST-3 trial, patients with angiography had less severe 
strokes at baseline (median NIHSS score of 9 versus 11; 
P=0.003), had baseline scanning slightly later (mean 180 ver-
sus 164 minutes; P<0.0001) and were randomized slightly later 
after stroke (mean 241 versus 231 minutes; P=0.019), and had 
better 6-month outcomes (median OHS 3 versus 4; P=0.001). 
There was no significant difference in age, sex, or treatment 
allocation between patients with angiograms versus the full 
IST-3 trial (Table II in the online-only Data Supplement). 
Among patients with angiography, there were no significant 
differences between alteplase and control groups (Table 1).
Angiography Findings: IST-3
In IST-3, 146 of 300 (48.7%) patients had intracranial arterial 
obstruction on angiography (Table 2). ICA (47/146=32.2%) 
or MCA mainstem (57/146=39.0%) obstruction was most 
common. For those with arterial obstruction, >1 arterial 
segment was affected in approximately half, 2 segments in 
54 of 146 (37.0%), and 3 segments in 15 of 146 (10.3%). 
From 288 patients with an IST-3 Angiography score, 104 
(36.1%) scored 0 to 2b, whereas 184 (63.9%) scored 3 to 4 
(Table 2 for concurrent TICI scores). The median clot burden 
score was 8 (2 segments affected). Similar proportions had 
good (48/135=35.6%), moderate (37/135=27.4%), or poor 
(50/135=37.0%) collateral scores.
Angiography, Stroke Severity, and 
Functional Outcome: IST-3
On univariate analysis, all categories of angiographic abnor-
mality were associated with significantly worse baseline 
stroke severity and poorer 6-month outcome (P<0.0001 for 
most; Table III in the online-only Data Supplement). A 3-way 
ANOVA found no interaction between any combination 
of the effects of TICI, clot burden, and collateral scores on 
OHS (F=0.814; P=0.564; Table IV in the online-only Data 
Supplement). In multivariable ordinal regression analysis, 
controlled for age, NIHSS, time from stroke onset to scan 
and alteplase treatment allocation; having a greater number 
of obstructed arterial segments (OR, 0.41; 95% confidence 
interval [CI], 0.22–0.76; P=0.005), a worse clot burden score 
(OR, 0.78; 95% CI, 0.62–0.97; P=0.026), or poorer collaterals 
(OR, 0.53; 95% CI, 0.32–0.85; P=0.009) were all indepen-
dent predictors of worse 6-month outcome, but not proximal 
versus distal (or ICA versus MCA) arterial obstruction, or the 
residual arterial caliber at the point of obstruction on IST-3 
angiography or TICI scores (Table 3).
Angiography and Effect of 
Intravenous Alteplase: IST-3
In IST-3, in multivariable ordinal regression, we found no sig-
nificant interactions between any individual angiogram fea-
ture and the effect of alteplase on 6-month OHS (Figure 1). 
There was a nonsignificant trend toward better outcomes after 
alteplase versus control among patients with obstructed (OR, 
1.86; 95% CI, 0.76–4.53; P=0.171) versus patent (OR, 0.72; 
95% CI, 0.42–1.25; P=0.241) arteries on the IST-3 angiogra-
phy score, P=0.075 for interaction (Figures 1 and 2).
Angiography and Effect of Intravenous 
Thrombolytics: Meta-Analysis of All Trials
We identified 11 RCTs of intravenous thrombolytics for 
ischemic stroke with baseline angiography (Figure I in the 
online-only Data Supplement) from which data were avail-
able for meta-analysis of 4 trials in addition to IST-3 (n=591). 
We included 2 trials of intravenous alteplase (288 patients 
from IST-3 and 87 from EPITHET19) and 3 trials of intrave-
nous desmoteplase (216 patients from DIAS, DIAS-2, and 
DEDAS).20–22 Meta-analysis showed that patients with arterial 
obstruction were significantly more likely to have better func-
tional outcome with intravenous thrombolytics versus control 
Table 1. Comparison of Baseline Data and Main Outcomes 
in IST-3 (Third International Stroke Trial) Patients With 
Angiography Allocated to Alteplase and Control (n=300)
 
Alteplase, 
n=147
Control, 
n=153
P Value for 
Difference
Age, y, median (IQR) 81 (73–86) 80 (69–85) 0.274
Male sex (%) 63 (42.9) 69 (45.1) 0.697
Time from stroke onset to 
baseline scan, min, mean (SD)
184 (82) 175 (78) 0.344
Time from stroke onset to 
randomization, min, mean (SD)
243 (82) 238 (79) 0.584
Baseline NIHSS, median (IQR) 10 (5–17) 9 (5–16) 0.603
Clinical stroke syndrome17 (%) 0.590
  TACI 49 (33.3) 50 (32.7)  
  PACI 64 (43.5) 68 (44.4)  
  LACI 11 (7.5) 14 (9.2)  
  POCI 23 (15.6) 20 (13.1)  
ASPECTS,18 median (IQR) 10 (8–10) 10 (8–10) 0.914
6-mo OHS, median (IQR) 3 (1–5) 3 (1–5) 0.726
6-mo mortality (%) 32 (21.8) 35 (22.9) 0.819
ASPECTS indicates Alberta Stroke Program Early CT Score; IQR, interquartile 
range; LACI, lacunar infarct; NIHSS, National Institutes of Health Stroke Scale; 
OHS, Oxford Handicap Scale; PACI, partial anterior circulation infarct; POCI, 
posterior circulation infarct; and TACI, total anterior circulation infarct.
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(OR, 2.07; 95% CI, 1.18–3.64; P=0.011) than were patients 
with patent arteries (intravenous thrombolytics versus con-
trol, OR, 0.88; 95% CI, 0.58–1.35; P=0.566), for interaction 
P=0.017 (Figure 3).
For meta-analysis of ICA versus MCA obstruction, data were 
only available from IST-3 and EPITHET (n=135+54=189, 
respectively) and we did not find any difference between 
response to intravenous thrombolytics in patients with ICA 
versus MCA obstruction (ICA obstruction: OR, 0.65; 95% CI, 
0.06–6.89; P=0.720; MCA obstruction: OR, 1.92; 95% CI, 
0.90–4.09; P=0.090) for interaction P=0.391 (Figure II in the 
online-only Data Supplement).
Discussion
This analysis of CTA and MRA data from 5 RCTs of intra-
venous thrombolytics (alteplase and desmoteplase), includ-
ing IST-3, comprising 591 patients treated within 6 hours of 
stroke, indicates that patients with angiographic obstruction/
occlusion benefit significantly more from intravenous throm-
bolytics than patients without arterial obstruction. Therefore, 
where endovascular therapy is not available,23 intravenous 
thrombolytics remain an important treatment. The significant 
interaction between angiography appearance and intravenous 
thrombolytics does not mean that patients with normal baseline 
angiography gain no benefit from intravenous thrombolytics24; 
the meta-analysis was neutral in this group, showing neither 
benefit or harm, but the sample is too small to exclude modest 
benefit or harm. It is important to remember that patients with 
normal angiograms may have arterial obstruction(s) too small 
to see on CTA/MRA, and intravenous thrombolytics may be 
beneficial in these patients.
In IST-3, we also demonstrate that having a greater num-
ber of obstructed arterial segments or poor collateral supply 
was associated with poor 6-month functional outcome, inde-
pendent of stroke severity and alteplase treatment, that is, 
alteplase was less likely to improve outcome in these patients. 
Those with a greater number of obstructed segments may, 
therefore, have the most to gain from endovascular therapy, 
which several RCTs have recently shown to be superior to 
  1 1 1
  0 0 1
Collateral score, n=135
  Good 22 26
  Moderate 23 14
  Poor 22 28
Clot burden and collateral scores were calculated only with anterior circulation 
obstruction. Obstruction was obscured or too peripheral for calculation of an 
IST-3 angiography, TICI or clot burden score in 12 cases. Not all patients with 
normal IST-3 angiography scores had normal TICI scores and vice versa. ACA 
indicates anterior cerebral artery; CTA, computed tomographic angiography; 
ICA, internal carotid artery; IST-3, Third International Stroke Trial; MCA, middle 
cerebral artery; MRA, magnetic resonance angiography; PCA, posterior cerebral 
artery; and TICI, Thrombolysis in Cerebral Infarction.
*Readers were asked is there an abnormal/occluded artery on CTA/MRA?
Table 2. Angiography Findings for the 300 Patients 
Randomized in IST-3 With CTA or MRA
 Alteplase, n=147 Control, n=153
Angiographic obstruction, n=300*
  Yes 72 74
  No 75 79
No. of obstructed arterial segments, n=146
  1 35 42
  2 29 25
  3 8 7
Largest arterial segment obstructed, n=146
  ICA 27 20
  MCA mainstem 25 32
  MCA Sylvian branch 15 16
  Basilar 2 3
  Vertebral 2 1
  Other 1 2
  ACA 0 0
  PCA 0 0
Location of angiographic obstruction, n=142
  Distal vessel only 13 13
  Proximal vessel only 21 25
  Proximal and distal 36 34
IST-3 angiography score, n=288
  4 75 80
  3 12 17
  2b 7 9
  2a 8 4
  1 15 17
  0 23 21
TICI score, n=288
  3 80 83
  2b 12 20
  2a 11 6
  1 11 18
  0 26 21
Clot burden score, n=123
  9 21 17
  8 12 17
  7 6 8
  6 4 6
  5 6 3
  4 4 4
  3 4 3
  2 3 2
(Continued )
Table 2. Continued
 Alteplase, n=147 Control, n=153
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intravenous alteplase alone among patients with angiogra-
phy-confirmed proximal intracranial arterial obstruction.25 
Consistent with our results, post hoc analysis of one of these 
endovascular treatment trials demonstrated that patients with 
poor collateral supply had poorer outcomes than those with 
good collaterals.26
We could not confirm in the meta-analysis that patients 
with MCA versus ICA obstruction responded differently to 
thrombolytics, but the sample available for this comparison 
was very small. In general, we were unable to identify avail-
able comparable trial data for most of the other angiogra-
phy characteristics assessed in IST-3. To better understand 
thrombolysis–angiography interactions, future RCTs of acute 
stroke therapy with CTA or MRA should examine location, 
extent, completeness of arterial obstruction, and adequacy of 
collaterals, to refine how these findings could help treatment 
decisions.
Strengths and Limitations
Strengths of IST-3 include our use of robust, validated meth-
ods for scan management, of scoring angiograms,7 with 
blinding of readers and moderate to substantial interobserver 
agreement.15 Limitations of IST-3, discussed previously, 
include the potential introduction of bias through its open 
design.6 Angiographic imaging was not a requirement of IST-
3, but some centers performed baseline CTA or MRA for 
ischemic stroke routinely; therefore, the angiography analy-
sis was preplanned to maximize knowledge gained from an 
RCT. The results of angiography were not used to determine 
trial eligibility, and at the time of IST-3 enrollment, there were 
virtually no data on how angiography results should be used 
in this context. Therefore, clinical uncertainty as to whether 
treatment with alteplase would be beneficial existed even 
for patients with large artery obstruction. Angiography was 
however performed in only 10% of IST-3 centers, potentially 
reflecting selection bias and restricting generalizability of the 
findings to all current stroke centers. Nevertheless, IST-3 angi-
ography represents real-world practice, where nearly 50% had 
angiographic obstruction27 and with 300 patients, is the largest 
angiography data set from an RCT of intravenous alteplase in 
ischemic stroke. Despite this, the wide CIs indicate that our 
sample is underpowered to estimate the effect of angiogra-
phy findings on alteplase response. We used dichotomies of 
better versus worse angiography scoring to simplify scalar 
data in IST-3. We acknowledge that different dichotomies of 
the same scalar data could provide different results, but we 
felt that our technique nevertheless provided a meaningful 
and useable summary. For the meta-analysis, slight inconsis-
tencies in angiogram scoring between trials mean that there 
is some overlap between categories (eg, Thrombolysis in 
Myocardial Infarction=2 is included in the better category for 
EPITHET but the worse category for the desmoteplase trials). 
Efforts to standardize angiogram rating in future trials should 
Table 3. Multivariable Ordinal Regression Analyses Testing 
for Independent Associations Between Angiographic Findings 
in IST-3 and 6-Month Functional Outcome on the OHS
 Odds Ratio
95% Confidence 
Interval P Value
Increased number of obstructed 
arterial segments, n=146
0.41 0.22–0.76 0.005
Obstructed proximal vs distal 
artery, n=142
0.45 0.20–1.02 0.055
Obstructed ICA vs MCA, n=135 0.85 0.40–1.81 0.679
Worse IST-3 angiography score, 
n=288
0.90 0.78–1.04 0.145
Worse TICI score, n=288 0.85 0.71–1.01 0.062
Worse Clot Burden Score, n=123 0.78 0.62–0.97 0.026
Poor Collateral Score, n=135 0.53 0.32–0.85 0.009
Odds ratio <1 indicates a worse outcome. Six-month OHS was the dependent 
variable for each separate model. Results are adjusted for patient age, time 
from stroke onset to scan, stroke severity (National Institutes of Health Stroke 
Scale), and alteplase treatment allocation. ICA indicates internal carotid artery; 
IST-3, Third International Stroke Trial; MCA, middle cerebral artery; OHS, Oxford 
Handicap Scale; and TICI, Thrombolysis in Cerebral Infarction.
Figure 1. IST-3 (Third International Stroke Trial), ordinal regression analyses, of the effect of alteplase treatment on outcome (Oxford 
Handicap Scale [OHS] as the dependent variable) in patients with more vs less normal results by different angiography features. Results 
represent odds ratio of better (right of vertical line) or worse (left of line) 6-month outcome with alteplase. Adjusted for age, time from 
stroke onset to scan, and stroke severity (National Institutes of Health Stroke Scale). ICA indicates internal carotid artery; MCA, middle 
cerebral artery; and TICI, Thrombolysis in Cerebral Infarction.
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be encouraged because this will facilitate between-trial com-
parisons and meta-analysis.28
Patients recruited in IST-3 after CTA or MRA were random-
ized and treated, on average, 10 minutes later than were those 
with only plain scans. The steep time dependency of alteplase 
effects on outcome means that even this small delay could 
reduce the potential benefit of treatment,29 particularly on a pop-
ulation level if angiography is performed nondiscriminately in 
all ischemic stroke patients. Efforts should be directed at mini-
mizing delays attributable to obtaining angiography in stroke.
Figure 2. IST-3 (Third International Stroke Trial), bar charts comparing Oxford Handicap Scale (OHS) distribution for alteplase and control 
groups in those with (A) and without (B) arterial obstruction. 
Figure 3. Meta-analysis of IST-3 (Third International Stroke Trial), EPITHET (Echoplanar Imaging Thrombolytic Evaluation Trial; alteplase), 
and the DIAS (Desmoteplase in Acute Ischemic Stroke), DIAS-2, and DEDAS (Dose Escalation of Desmoteplase for Acute Ischemic 
Stroke; desmoteplase) trials comparing the effect of intravenous thrombolytics on functional outcome between patients with arterial 
patency vs obstruction. Raw treatment data were unavailable for the Desmoteplase trials. Results represent odds ratio of better (right 
of vertical line) or worse (left of line) outcome after thrombolytics. Open circles represent arterial patency (test for heterogeneity, I2=0%). 
Closed circles represent arterial obstruction (I2=16%). TIMI indicates Thrombolysis in Myocardial Infarction.
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Conclusions
Intravenous thrombolytic therapy is significantly more effec-
tive in improving functional outcome in patients present-
ing with ischemic stroke who have arterial obstruction than 
in those with apparently patent arteries on CTA or MRA. 
Intravenous thrombolytics, therefore, remain an important 
treatment option. The data are too sparse to determine, in this 
analysis, whether patients without apparent arterial obstruc-
tion benefit from intravenous thrombolytics, bearing in mind 
that these patients may have thrombus too small to detect on 
CTA or MRA.
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